These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22481083)

  • 1. Apoptosome-dependent caspase activation proteins as prognostic markers in Stage II and III colorectal cancer.
    Hector S; Conlon S; Schmid J; Dicker P; Cummins RJ; Concannon CG; Johnston PG; Kay EW; Prehn JH
    Br J Cancer; 2012 Apr; 106(9):1499-1505. PubMed ID: 22481083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical application of a systems model of apoptosis execution for the prediction of colorectal cancer therapy responses and personalisation of therapy.
    Hector S; Rehm M; Schmid J; Kehoe J; McCawley N; Dicker P; Murray F; McNamara D; Kay EW; Concannon CG; Huber HJ; Prehn JH
    Gut; 2012 May; 61(5):725-33. PubMed ID: 22082587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic overview of chemotherapy effects in colorectal cancer.
    Ragnhammar P; Hafström L; Nygren P; Glimelius B;
    Acta Oncol; 2001; 40(2-3):282-308. PubMed ID: 11441937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The apoptosome molecular timer synergises with XIAP to suppress apoptosis execution and contributes to prognosticating survival in colorectal cancer.
    Fullstone G; Bauer TL; Guttà C; Salvucci M; Prehn JHM; Rehm M
    Cell Death Differ; 2020 Oct; 27(10):2828-2842. PubMed ID: 32341447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
    Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G
    Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
    Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
    JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrity of XIAP is essential for effective activity recovery of apoptosome and its downstream caspases by Smac/Diablo.
    Attaran-Bandarabadi F; Abhari BA; Neishabouri SH; Davoodi J
    Int J Biol Macromol; 2017 Aug; 101():283-289. PubMed ID: 28322955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
    Stanisavljević L; Myklebust MP; Leh S; Dahl O
    Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemopreventive effects of non-steroidal anti-inflammatory drugs in early neoplasm of experimental colorectal cancer: an apoptosome study.
    Vaish V; Tanwar L; Kaur J; Sanyal SN
    J Gastrointest Cancer; 2011 Dec; 42(4):195-203. PubMed ID: 20623380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical impact of adjuvant chemotherapy on patients with stage III colorectal cancer: l-LV/5FU chemotherapy as a modified RPMI regimen is an independent prognostic factor for survival.
    Hotta T; Takifuji K; Arii K; Yokoyama S; Matsuda K; Higashiguchi T; Tominaga T; Oku Y; Yamaue H
    Anticancer Res; 2006; 26(2B):1425-32. PubMed ID: 16619554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The role of the apoptosome in the activation of procaspase-9].
    Marek Ł
    Postepy Hig Med Dosw (Online); 2013 Feb; 67():54-64. PubMed ID: 23475483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial.
    Song N; Pogue-Geile KL; Gavin PG; Yothers G; Kim SR; Johnson NL; Lipchik C; Allegra CJ; Petrelli NJ; O'Connell MJ; Wolmark N; Paik S
    JAMA Oncol; 2016 Sep; 2(9):1162-9. PubMed ID: 27270348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide.
    Yang L; Mashima T; Sato S; Mochizuki M; Sakamoto H; Yamori T; Oh-Hara T; Tsuruo T
    Cancer Res; 2003 Feb; 63(4):831-7. PubMed ID: 12591734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.
    Soong R; Shah N; Salto-Tellez M; Tai BC; Soo RA; Han HC; Ng SS; Tan WL; Zeps N; Joseph D; Diasio RB; Iacopetta B
    Ann Oncol; 2008 May; 19(5):915-9. PubMed ID: 18245778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apoptosome: a platform for the activation of initiator caspases.
    Bao Q; Shi Y
    Cell Death Differ; 2007 Jan; 14(1):56-65. PubMed ID: 16977332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy.
    Edler D; Glimelius B; Hallström M; Jakobsen A; Johnston PG; Magnusson I; Ragnhammar P; Blomgren H
    J Clin Oncol; 2002 Apr; 20(7):1721-8. PubMed ID: 11919227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized comparative study of surgical adjuvant chemotherapy using 5-fluorouracil and dl-leucovorin with CDDP, 5-FU and dl-leucovorin for advanced colorectal cancer.
    Okabe S; Arai T; Yamashita H; Sugihara K; Sasaki T
    J Gastroenterol Hepatol; 2004 Jan; 19(1):56-62. PubMed ID: 14675243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy.
    Boye K; Jacob H; Frikstad KA; Nesland JM; Maelandsmo GM; Dahl O; Nesbakken A; Flatmark K
    Cancer Med; 2016 Aug; 5(8):1840-9. PubMed ID: 27273130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial.
    Nordlinger B; Rougier P; Arnaud JP; Debois M; Wils J; Ollier JC; Grobost O; Lasser P; Wals J; Lacourt J; Seitz JF; Guimares dos Santos J; Bleiberg H; Mackiewickz R; Conroy T; Bouché O; Morin T; Baila L; van Cutsem E; Bedenne L
    Lancet Oncol; 2005 Jul; 6(7):459-68. PubMed ID: 15992694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.